GlassScriptPhysician profile
Thomas M Reed
NPI 1700979879
$3,497.93
in general payments reported to CMS, 2019-2025
13 companies · $1,102 in 2025
The $1,102 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.98 · 2020: $45.89 · 2021: $375 · 2022: $475 · 2023: $694 · 2024: $748 · 2025: $1,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,544.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,422.27 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $872.75 | 2021-2025 | Airsupra, Breztri, Tezspire |
| Pfizer INC. | $341.39 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $298.98 | 2021-2023 | Stiolto Respimat |
| Verona Pharma, INC. | $188.64 | 2025 | Ohtuvayre |
| Electromed, INC. | $92.66 | 2025 | Smartvest |
| Insmed, INC. | $68.38 | 2025 | Arikayce, Brinsupri |
| Inspire Medical Systems, INC. | $63.23 | 2024 | Inspire |
| Novo Nordisk INC | $53.18 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $32.96 | 2025 | Zepbound, Mounjaro |
| Inogen, INC. | $25.86 | 2024 | |
| Medtronic Vascular, INC. | $19.49 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $18.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.